Two years' follow-up of rivastigmine treatment in Huntington disease

Clinical Neuropharmacology

Volumn 30, Issue 1, 2007, Pages 43-46

  De Tommaso, Marina ^a,b   Difruscolo, Olimpia ^a   Sciruicchio, Vittorio ^a   Specchio, Nicola ^a   Livrea, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Cognitive impairment; Huntington disease; Long term therapy; Motor performance; Rivastigmine

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; RIVASTIGMINE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE;

ADULT; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES;

EID: 33846815309     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000240945.44370.f0     Document Type: Article

References (11)

1. de Tommaso M, Specchio N, Sciruicchio V, et al. Efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004;19(12):1516-1518.
2. Shoulson I. Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
3. Pisani A, Bonsi P, Picconi B, et al. Role of tonically-active neurons in the control of striatal function: cellular mechanism and behavioral correlates. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:211-230.
4. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised, controlled trial. BMJ 1999;318:633-638.
5. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;1:CD004747.
6. Measso G, Cavarzeran F, Zappalà G, et al. The Mini Mental State Examination: normative study of an Italian random sample. Dev Neuropsychol 1993;9:77-85.
7. Marsden CD, Schachter M. Assessment of extrapyramidal disorders. Br J Clin Pharmacol 1981;11:129-151.
8. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health Education and Welfare; 1976:534-537.
9. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
10. Brandt J, Bylsma FW, Gross R, et al. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996;46:527-531.
11. Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004;19(2):51-62.